Tagrisso 80 mg is a prescription anticancer medicine containing osimertinib. It is a targeted therapy used in specific treatment settings for non-small cell lung cancer (NSCLC) associated with certain epidermal growth factor receptor (EGFR) mutations.
Like other cancer medicines, osimertinib can cause side effects. Some are relatively common and manageable, while others can be serious and require prompt medical assessment. The type and severity of reactions vary from patient to patient, and not everyone experiences the same symptoms.
Understanding potential adverse reactions can help patients recognize changes in their health and communicate effectively with their oncology team. This page provides general safety information and does not replace the current official prescribing information or individualized medical advice.
1. What Are the Common Side Effects of Tagrisso?
Commonly reported side effects of osimertinib include diarrhea, skin rash, dry skin, nail changes and inflammation of the mouth. The frequency and severity of these reactions can vary according to the patient and treatment setting.
Some symptoms may be mild, while others can interfere with eating, sleeping, hydration or daily activities. Patients should report persistent or worsening symptoms rather than assuming that every reaction is an unavoidable part of treatment.
The healthcare team can evaluate the symptoms, recommend appropriate supportive care and determine whether further investigation or a change in treatment is necessary.
2. Diarrhea
Diarrhea is a recognized side effect of osimertinib. It may range from mild, temporary changes in bowel habits to more persistent symptoms that interfere with daily life.
Ongoing diarrhea can contribute to dehydration, weakness and electrolyte disturbances, particularly when fluid intake is inadequate. Patients should inform their healthcare team if diarrhea continues, becomes severe or is accompanied by dizziness, reduced urination or difficulty maintaining hydration.
The clinician can recommend appropriate management based on symptom severity and the patient’s overall condition. Patients should not start additional medicines or independently change their cancer treatment without appropriate guidance.
Severe diarrhea, especially when associated with marked weakness, faintness or inability to maintain fluids, warrants urgent medical assessment.
3. Skin Rash
Skin rash is another commonly reported reaction during osimertinib treatment. It may appear as redness, bumps or irritation and can affect areas such as the face, chest or back.
The severity can vary. Mild irritation may be manageable, but a persistent, painful or worsening rash should be assessed by a healthcare professional. Skin changes accompanied by blistering, peeling, swelling or signs of infection require prompt medical attention.
Patients should discuss suitable skin-care measures with their healthcare team. They should avoid assuming that every rash is harmless, particularly when it develops rapidly or is associated with other concerning symptoms.
4. Dry Skin and Itching
Dry skin and itching may occur during treatment. These symptoms can cause discomfort and may become more troublesome when the skin is already irritated.
Patients should report persistent itching, cracking, bleeding or other skin changes that interfere with daily activities. A healthcare professional can determine whether the symptoms are related to treatment and recommend suitable care.
If the skin becomes severely inflamed, develops blisters or shows signs of infection, prompt assessment is important. Patients should avoid using unfamiliar medicated creams or supplements without checking their suitability with a healthcare professional.
5. Nail Changes and Inflammation Around the Nails
Osimertinib may cause nail changes, including inflammation around the nail edges. Symptoms can include tenderness, redness, swelling or discomfort during everyday activities.
Patients should report worsening pain, discharge, spreading redness or other signs that could suggest infection. A clinician can assess the problem and advise on appropriate management.
Nail symptoms should not be ignored when they interfere with walking, handling objects or other routine tasks. Patients should not attempt to treat a suspected infection using leftover medicines or products that have not been recommended for them.
6. Mouth Inflammation and Sores
Inflammation of the mouth, sometimes called stomatitis, may occur during treatment. Symptoms can include soreness, irritation or mouth ulcers that make eating and drinking uncomfortable.
Patients should tell their healthcare team if mouth symptoms persist, worsen or interfere with nutrition or hydration. The clinician can assess the severity and recommend appropriate supportive measures.
Difficulty swallowing, inability to maintain fluid intake or severe mouth pain requires prompt medical advice. Patients should not assume that severe mouth symptoms are insignificant simply because they affect only the mouth.
7. Serious Lung Problems
One of the most important safety concerns associated with osimertinib is interstitial lung disease (ILD) or pneumonitis. These conditions involve inflammation or injury in lung tissue and can be serious.
Warning symptoms may include new or worsening shortness of breath, persistent cough, fever or other unexplained respiratory changes. These symptoms can have several causes, so professional assessment is needed to determine what is happening.
Patients should contact their healthcare team promptly if these symptoms develop. Severe breathing difficulty or rapidly worsening respiratory symptoms require emergency medical assistance.
Patients should not wait for a routine appointment or attempt to diagnose pulmonary toxicity themselves. Decisions about interrupting or discontinuing treatment must be made according to the clinical assessment and applicable prescribing information.
8. Heart Rhythm Problems and QT Prolongation
Osimertinib may prolong the QT interval, which is a measurement of the heart’s electrical activity. Significant QT prolongation can increase the risk of potentially serious heart rhythm disturbances in susceptible patients.
Symptoms such as fainting, palpitations or a rapid or irregular heartbeat require medical attention. These symptoms are not specific to QT prolongation, but they should not be ignored.
The healthcare professional may review other medicines, assess relevant risk factors and recommend electrocardiography or laboratory testing where appropriate. Patients should disclose medicines that may affect heart rhythm and should not independently stop prescribed medicines.
Fainting accompanied by chest pain, severe weakness or breathing difficulty requires emergency assessment.
9. Cardiomyopathy and Changes in Heart Function
Cardiomyopathy, which affects the heart muscle, is another serious potential adverse reaction associated with osimertinib.
Possible symptoms of reduced heart function include worsening breathlessness, unexplained fatigue or swelling. These symptoms can also result from other conditions, including the underlying illness, and require professional assessment rather than self-diagnosis.
Patients with a history of significant heart disease should discuss this with their oncology team before treatment. The clinician will determine whether heart-function assessment is appropriate and whether additional monitoring is needed.
New or worsening symptoms that could indicate heart problems should be reported promptly.
10. Eye Problems and Keratitis
Osimertinib may cause eye-related problems, including keratitis, which is inflammation of the cornea. Patients should report eye pain, redness, light sensitivity, excessive tearing or changes in vision.
Eye symptoms may have different causes, and a healthcare professional can determine whether an examination or referral to an eye specialist is required.
Sudden changes in vision, severe eye pain or significant visual deterioration require urgent assessment. Patients should not rely on online information to decide that an eye symptom is harmless.
11. Aplastic Anemia and Blood-Related Symptoms
Aplastic anemia is a rare but serious potential risk associated with osimertinib. It involves reduced production of blood cells by the bone marrow.
Patients should promptly report unusual bruising, unexplained bleeding, marked weakness, unusual infections or other concerning symptoms. These symptoms can arise for several reasons and cannot establish a diagnosis by themselves.
The healthcare professional may recommend laboratory testing or other investigations to determine the cause. Patients should follow the monitoring plan provided by their oncology team.
12. Allergic Reactions and Other Unexpected Symptoms
Patients should report any unexpected or concerning reaction that develops during treatment, even if the symptom is not listed in this overview.
Symptoms such as swelling of the face or throat, severe breathing difficulty or other signs of a potentially severe allergic reaction require emergency medical assistance.
A website cannot provide a complete list of every possible adverse reaction. Patients should consult the current patient leaflet and contact their healthcare team when they are uncertain whether a symptom may be related to treatment.
13. How Are Tagrisso Side Effects Managed?
Management depends on the type of reaction, its severity and the patient’s overall clinical condition. The healthcare team may recommend supportive care, further testing, treatment interruption, dose modification or discontinuation when indicated by the official prescribing information.
Patients should keep a record of symptoms, including when they began, how often they occur and whether they are getting worse. This information can help the clinician assess the problem.
Patients should not independently reduce the dose, take extra tablets or stop treatment. If a potentially serious reaction develops, they should seek prompt medical assessment and follow professional instructions.
14. Factors That May Affect Side Effects
Side effects can vary according to individual health, other medicines, the treatment setting and other clinical factors.
The healthcare team should review the patient’s medical history, including relevant heart, lung and eye conditions, before treatment. All prescription medicines, nonprescription products, vitamins and herbal supplements should also be disclosed because interactions or overlapping adverse effects may influence the safety of treatment.
Age, general health and the presence of other medical conditions may affect how symptoms are assessed and managed. However, no single factor can reliably predict every reaction.
15. When Should You Seek Medical Attention?
Patients should contact their healthcare team promptly for persistent diarrhea, worsening skin reactions, mouth sores that interfere with eating or drinking, unusual bruising or bleeding, or other new symptoms that concern them.
Seek urgent assessment for new or worsening shortness of breath, persistent cough, significant eye pain, visual changes, fainting or a rapid or irregular heartbeat. Severe or rapidly worsening symptoms require emergency medical assistance.
Do not delay emergency care while searching for information online or waiting for a response from a website.
Frequently Asked Questions About Tagrisso Side Effects
Does everyone experience side effects from Tagrisso?
No. Side effects vary between patients. Some people experience mild symptoms, while others develop more significant reactions. Regular monitoring remains important even when no symptoms are present.
Can Tagrisso cause diarrhea?
Yes. Diarrhea is a recognized adverse reaction. Persistent or severe symptoms should be reported because they may lead to dehydration or other complications.
Is a skin rash always a sign of a serious reaction?
No. Rashes vary in severity, but a worsening, painful or blistering rash requires medical assessment. Patients should seek professional advice rather than assume that a rash is harmless.
Can Tagrisso affect the heart?
Yes. Important potential risks include QT prolongation and cardiomyopathy. The healthcare team determines whether cardiac monitoring is appropriate based on the prescribing information and individual risk factors.
Should I stop taking Tagrisso if I develop side effects?
Do not make an independent treatment decision. Contact your oncology team for guidance. Serious symptoms require urgent assessment, and treatment changes should be managed by a qualified healthcare professional.
How can I report a suspected side effect?
Contact your prescribing clinician or pharmacist. They can assess the reaction and explain whether it should also be reported through the applicable medicine safety reporting system in your country.
Conclusion
Tagrisso 80 mg can cause common side effects, including diarrhea, rash, dry skin, nail changes and mouth inflammation. Serious risks include interstitial lung disease or pneumonitis, QT prolongation, cardiomyopathy, keratitis and aplastic anemia.
Recognizing symptoms early, attending scheduled monitoring appointments and communicating openly with the oncology team are important parts of treatment safety. Patients should never ignore severe symptoms or make independent changes to their prescribed regimen.
Medical Disclaimer: This page provides general educational information and does not replace professional medical advice, diagnosis, treatment or the current official prescribing information. Individual risks and treatment decisions must be assessed by a qualified healthcare professional. Seek emergency assistance for severe or rapidly worsening symptoms.